B

iotech executives appear slightly less concerned about drug pricing than in the recent past, according to a new analysis, but the continued pressure from payers and lawmakers to bring down costs does still weigh on them.

A review of risk factors cited by the 100 largest companies listed in the Nasdaq Biotechnology Index found 84 percent cited worries over pricing pressures, according to the BDO advisory and consulting firm, which examined the most recent crop of annual filings with the US Securities and Exchange Commission.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy